Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development.

@article{Birzniece2017TamoxifenRH,
  title={Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development.},
  author={V. Birzniece and P. Barrett and K. Ho},
  journal={European journal of endocrinology},
  year={2017},
  volume={177 2},
  pages={
          137-143
        }
}
CONTEXT Growth hormone (GH) stimulates hepatic synthesis of very-low-density lipoproteins (VLDL), whereas hepatic steatosis develops as a result of GH deficiency. Steatosis is also a complication of tamoxifen treatment, the cause of which is not known. As tamoxifen inhibits the secretion and action of GH, we hypothesize that it induces steatosis by inhibiting hepatic VLDL export. AIM To investigate whether tamoxifen reduces hepatic VLDL secretion. DESIGN Eight healthy, normolipidemic women… Expand
Hepatic actions of androgens in the regulation of metabolism
  • V. Birzniece
  • Medicine
  • Current opinion in endocrinology, diabetes, and obesity
  • 2018
Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?
Tamoxifen in horses: pharmacokinetics and safety study
Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells
Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
...
1
2
...

References

SHOWING 1-10 OF 41 REFERENCES
Direct effects of growth hormone on production and secretion of apolipoprotein B from rat hepatocytes.
Paracrine regulation of growth hormone secretion by estrogen in women.
Tamoxifen Inhibits Lipoprotein Activity: In vivo and in vitro Studies
...
1
2
3
4
5
...